Incyte Corporation (NASDAQ: INCY) announced this morning that INCB18424
(also referred to as INCB018424), its selective, orally available janus
kinase (JAK) inhibitor, will be the subject of three oral presentations
at the 51st American Society of Hematology (ASH) Annual
Meeting in New Orleans.
Srdan Verstovsek, M.D., Ph.D., Associate Professor, Leukemia Department,
Myeloproliferative Disorders Program Leader, University of Texas M.D.
Anderson Cancer Center, and the principal investigator for the INCB18424
myeloproliferative neoplasms clinical programs, stated, "INCB18424
continues to provide durable and previously unachievable clinical
benefits in patients with myelofibrosis with or without JAK2 activating
mutations. It is equally gratifying to see significant clinical benefits
in patients with advanced polycythemia vera and essential
thrombocythemia including normalization of blood counts, normalization
of hematocrit without the need for phlebotomy, rapid and durable
reductions in enlarged spleens as well as rapid and durable reductions
in symptoms, particularly pruritus.
“Additionally, in an exploratory trial in highly refractory patients
with secondary acute myeloid leukemia and other leukemias for which no
standard therapies are likely to lead to a durable remission, it is
encouraging to see patients obtain clinical benefit including the
achievement of stable disease as well as complete and partial responses.
Our experience with INCB18424 in these highly refractory leukemia
patients, along with the growing body of evidence indicating that JAK
activation may play a determining role in a number of hematologic
malignancies, suggests that use of a selective JAK inhibitor may help
provide underserved patients in multiple hematological cancers with
improved clinical outcomes.”